Figures computed from official regulatory filings — .
Analysttarget 16.33 USD (+318%) · consensus 5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 13.5% · institutions 37.44% · short 2.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Edesa Biotech, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
47 buys16 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | $800K | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brooks Michael Jtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sistilli Carlo | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Olson Charles V | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chypyha Joan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Weiler Peter J. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Liu Da David | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MacDonald Sean Arthur | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marshall Patrick | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nijhawan Pardeeptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brooks Michael Jtrack record | Buy | $3.1K | conv 47First in 12mo | SEC |
| Nijhawan Pardeeptrack record | Buy | $6.6K | conv 17 | SEC |
| Nijhawan Pardeeptrack record | Buy | $39K | conv 29 | SEC |
| Nijhawan Pardeeptrack record | Buy | $42.6K | conv 32 | SEC |
| Nijhawan Pardeeptrack record | Buy | $36.3K | conv 29 | SEC |
| Nijhawan Pardeeptrack record | Buy | $2.3K | conv 17 | SEC |
| Nijhawan Pardeeptrack record | Buy | $4K | conv 17 | SEC |
| Nijhawan Pardeeptrack record | Buy | $32.5K | conv 59Unusual sizeFirst in 12mo | SEC |
| Nijhawan Pardeeptrack record | Buy | $66.6K | conv 43Unusual size | SEC |